Greening and digitalizing pharmaceutical manufacturing is one of the grand challenges of Europe's pharma-industry. It offers a significant opportunity to boost productivity, improve competitiveness and reduce the industry large environmental footprint. Current progress is impaired by shortage of trained engineers and scientists, who can design green and digital pharmaceutical processes.

This MSCA doctoral network will focus on addressing the skills gaps, to deliver a cohort of highly-skilled and trained PhD graduates that will lead the green and digital transformation of the pharmaceutical manufacturing, both in academic and industrial environments. The consortium brings together 8 industry partners, 10 universities, and 1 research organisation to address the most urgent topics in continuous green manufacturing. On a scientific level, GREENDIGIPHARMA will focus on research and innovation activities that aim at integrating 5 breakthrough concepts: CAT-to-PHARMA, WASTE-to-PHARMA, FLOW-to-PHARMA, PUR-to-PHARMA, and DIGITAL to PHARMA. This will develop greener routes to prepare pharmaceutical products, promoting the adoption of novel technologies (flow synthesis instead batch methods, heterogeneous nano and biocatalysis in lieu of homogeneous catalysts, renewable carbon sources, novel purification methods, digitalization tools) for sustainable manufacturing.